🌕 Gate Square · Mid-Autumn Creator Incentive Program is Live!
Share trending topic posts, and split $5,000 in prizes! 🎁
👉 Check details & join: https://www.gate.com/campaigns/1953
💝 New users: Post for the first time and complete the interaction tasks to share $600 newcomer pool!
🔥 Today's Hot Topic: #MyTopAICoin#
Altcoins are heating up, AI tokens rising! #WLD# and #KAITO# lead the surge, with WLD up nearly 48% in a single day. AI, IO, VIRTUAL follow suit. Which potential AI coins are you eyeing? Share your investment insights!
💡 Post Ideas:
1️⃣ How do you see AI tokens evolving?
2️⃣ Wh
The weight loss effect of Novo Nordisk's new drug is not as expected, big dump before the US stock market opens
On December 20th, Jinshi data reported that Novo Nordisk announced on Friday that its experimental next-generation weight-loss drug CagriSema helped overweight patients lose 22.7% of their weight in late-stage trials, lower than the expected 25%, which caused a significant fall in the company's stock price. This lower-than-expected data is a blow to Novo Nordisk, which had hoped that CagriSema would be a more powerful product than its previous generation weight-loss drug Wegovy, to replace it. Investors and analysts have been eagerly awaiting these data to test whether Novo Nordisk has a strong follow-up product to replace Wegovy in the fiercely competitive anti-obesity market. After the results were announced on Friday, Novo Nordisk's stock price fell big dump by 22% in pre-market trading on the US stock market.